HEOR Archives -

Towards a new understanding of cardiovascular risk in diabetes

Market Access/ News/ News/ News/ Sales and Marketing

NICE unlocks use of Amarin’s Vazkepa in 425k NHS patients

Phil Taylor Amarin, cardiovascular disease, HEOR, NHS, NICE, reimbursement, Vazkepa 0 Comment

Health technology assessment (HTA) agency NICE has finalised its guidance on Amarin’s Vazkepa, clearing the path for GPs

NICE unlocks use of Amarin’s Vazkepa in 425k NHS patients

https://pharmaphorum.com/news/nice-unlocks-use-of-amarins-vazkepa-in-425k-nhs-patients/

Radiology technician examens mammography test

Market Access/ News/ News/ News/ Oncology

NICE backs two new breast cancer drugs for NHS use

Phil Taylor breast cancer, Gilead Sciences, HEOR, NHS, NICE, Novartis, Oncology, Piqray, Trodelvy 0 Comment

Cost-effectiveness watchdog NICE has recommended routine NHS use of two new therapies for women with advanced breast cancer

NICE backs two new breast cancer drugs for NHS use

https://pharmaphorum.com/news/nice-backs-two-new-breast-cancer-drugs-for-nhs-use/

Janssen J&J Johnson and Johnson pharmaceutical companies

Market Access/ News/ News/ News/ Patients

NICE makes J&J’s Tremfya more accessible in England and Wales

Phil Taylor HEOR, Johnson & Johnson, NICE, psoriatic arthritis, Tremfya 0 Comment

NICE has updated its recommendations for NHS use of Johnson & Johnson’s IL-23 inhibitor Tremfya in the treatment

NICE makes J&J’s Tremfya more accessible in England and Wales

https://pharmaphorum.com/news/nice-makes-jjs-tremfya-more-accessible-in-england-and-wales/

Market Access/ News/ News

BMS’ Opdivo gets NHS use as adjuvant bladder cancer therapy

Phil Taylor access, Bristol-Myers Squibb, HEOR, NHS, NICE, Opdivo, UK, urothelial carcinoma 0 Comment

NICE has recommended routine use of Bristol-Myers Squibb’s Opdivo for the adjuvant treatment of some patients with urothelial

BMS’ Opdivo gets NHS use as adjuvant bladder cancer therapy

https://pharmaphorum.com/news/bms-opdivo-gets-nhs-use-as-adjuvant-bladder-cancer-therapy/

Market Access/ News/ News/ News/ News/ Oncology/ Patients

Lilly’s Verzenios gets NICE blessing for early-stage breast cancer

Phil Taylor breast cancer, Eli Lilly, HEOR, NHS, NICE, Oncology, Verzenio 0 Comment

Thousands more people with breast cancer in England look set to be eligible for routine treatment with Eli

Lilly’s Verzenios gets NICE blessing for early-stage breast cancer

https://pharmaphorum.com/news/lillys-verzenios-gets-nice-blessing-for-early-stage-breast-cancer/

Market Access/ News/ News

NICE backs Astellas’ oral therapy Evrenzo for anaemia in kidney disease

Phil Taylor anaemia, Astellas, chronic kidney disease, Evrenzo, HEOR, NHS, NICE 0 Comment

Astellas’ oral HIF-PH inhibitor Evrenzo has become the first drug in the class to be recommended for routine

NICE backs Astellas’ oral therapy Evrenzo for anaemia in kidney disease

https://pharmaphorum.com/news/nice-backs-astellas-oral-therapy-evrenzo-for-anaemia-in-kidney-disease/

Market Access/ News/ News

NICE backs NHS use of Amarin’s Vazkepa for cardiovascular risk reduction

Phil Taylor Amarin, cardiovascular disease, HEOR, NHS, NICE, reimbursement, Vazkepa 0 Comment

Around 425,000 people in England and Wales with cardiovascular disease who are at risk of a secondary stroke

NICE backs NHS use of Amarin’s Vazkepa for cardiovascular risk reduction

https://pharmaphorum.com/news/nice-backs-nhs-use-of-amarins-vazkepa-for-cardiovascular-risk-reduction/

Market Access/ News/ News

MHRA gives Alnylam ‘innovation passport’ for hypertension drug zilebesiran

Phil Taylor Alnylam, HEOR, hypertension, innovation passport, MHRA, NHS, regulatory, UK, zilebesiran 0 Comment

The UK medicines regulator has awarded Alnylam’s RNAi-based therapy zilebesiran for hypertension an ‘innovation passport‘, a designation designed

MHRA gives Alnylam ‘innovation passport’ for hypertension drug zilebesiran

https://pharmaphorum.com/news/mhra-gives-alnylam-innovation-passport-for-hypertension-drug-zilebesiran/

Market Access/ News/ News/ News/ Oncology

NICE finds solution to making Keytruda available for TNBC

Phil Taylor HEOR, Keytruda, market access, Merck & Co, NICE, Roche, Tecentriq, triple negative breast cancer 0 Comment

Around 100 patients in England and Wales with triple negative breast cancer (TNBC) that has spread to other

NICE finds solution to making Keytruda available for TNBC

https://pharmaphorum.com/news/nice-finds-solution-to-making-keytruda-available-for-tnbc/

Trending

HEOR

Login